Drugs Containing Excipient (Inactive Ingredient) POVIDONE K30

« Back to Dashboard

Branded drugs containing POVIDONE K30 excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Genentech Inc	VALCYTE	valganciclovir	0004-0038	POVIDONE K30
Genentech Inc	INVIRASE	saquinavir mesylate	0004-0244	POVIDONE K30
Genentech Inc	TAMIFLU	oseltamivir phosphate	0004-0802	POVIDONE K30
Merck Sharp & Dohme LLC	JANUMET	sitagliptin and metformin hydrochloride	0006-0078	POVIDONE K30

Generic drugs containing POVIDONE K30 excipient

Company	Ingredient	NDC	Excipient
Genentech Inc	valganciclovir	0004-0038	POVIDONE K30
Genentech Inc	saquinavir mesylate	0004-0244	POVIDONE K30
Genentech Inc	oseltamivir phosphate	0004-0802	POVIDONE K30
Merck Sharp & Dohme LLC	sitagliptin and metformin hydrochloride	0006-0078	POVIDONE K30

Povidone K30 Market Dynamics, Pricing, Supply Chain, and Financial Outlook

Last updated: September 25, 2026

Povidone K30 is a high-volume pharmaceutical excipient used mainly as a tablet binder, solubilizer, film former, and stabilizer. Demand is tied to oral solid-dose manufacturing, generic drug production, and formulation development. The market is fragmented across multinational chemical companies and Asian manufacturers, while pharmaceutical-grade supply remains more concentrated than industrial-grade supply.

Published market estimates vary because suppliers rarely report Povidone K30 revenue separately from broader povidone, polyvinylpyrrolidone, or pharmaceutical excipient portfolios. The commercial outlook is positive but moderate: volume growth is likely to remain in the low-to-mid single digits, with revenue growth supported by pharmaceutical-grade premiums, regulatory qualification, and demand for higher-purity and lower-peroxide grades.

What is Povidone K30 and how is it used in pharmaceutical formulations?

Povidone K30 is a pharmaceutical-grade polyvinylpyrrolidone, or PVP, with a nominal K-value of 30. The K-value correlates with molecular weight and solution viscosity. Povidone K30 is generally selected when formulators need a balance between binding performance, solubility, viscosity, and processability.

Typical pharmaceutical applications include:

Application	Function of Povidone K30	Commercial relevance
Immediate-release tablets	Wet-granulation binder	Largest and most established use
Direct compression	Binder and compactibility aid	Growing where low-moisture processing is preferred
Oral liquids	Solubilizer and viscosity modifier	Smaller volume, higher formulation value
Poorly soluble drugs	Solubilizer or amorphous-solid-dispersion carrier	Higher-growth technical application
Film coatings	Film former and adhesion promoter	Often used with other polymers
Topical products	Stabilizer and film-forming agent	Moderate demand
Ophthalmic and specialty formulations	Solubilizer or viscosity modifier	Requires tighter impurity controls

Povidone K30 is water-soluble, chemically stable across a broad formulation range, and compatible with many active pharmaceutical ingredients. Its main technical limitation is hygroscopicity. Moisture can affect powder flow, granulation behavior, tablet hardness, and long-term stability.

The grade is identified by viscosity rather than a single molecular-weight value. Pharmacopoeial requirements typically address identity, viscosity, nitrogen content, residual monomer, aldehydes, ash, water, and related purity attributes (United States Pharmacopeia, 2024).

How large is the Povidone K30 market?

The global Povidone K30 market is best analyzed as a subset of the broader pharmaceutical povidone and excipient market. Public market studies commonly place the broader povidone market in the several-hundred-million-dollar range, but estimates differ because they use different definitions of pharmaceutical grade, geographic coverage, and inclusion of industrial PVP.

A practical commercial estimate is:

Market segment	Indicative 2024 position	Expected growth profile
Pharmaceutical-grade povidone, all K-values	Several hundred million dollars globally	Mid-single-digit growth
Povidone K30	Largest or one of the largest individual grades	Low-to-mid single-digit volume growth
High-purity and specialty PVP	Smaller base	Mid- to high-single-digit growth
Industrial and technical PVP	Material but separate from pharmaceutical demand	Cyclical and price-sensitive

Povidone K30 benefits from its position as a standard formulation excipient. Unlike novel excipients, it does not require widespread customer education or extensive formulation adoption. It is present in many established tablet products, including generic medicines.

Growth is constrained by the maturity of oral solid dosage forms, substitution by coprocessed excipients, and the ability of formulators to reduce binder loading. Dry granulation, direct compression, copovidone, crospovidone, hypromellose, pregelatinized starch, and cellulose derivatives compete for some applications.

What drives demand for Povidone K30?

Generic drug manufacturing

Generic drug producers remain the largest structural demand driver. Povidone K30 is used in immediate-release formulations across analgesics, anti-infectives, cardiovascular medicines, central nervous system products, and other high-volume categories.

Generic manufacturers favor excipients with:

• Established compendial status
• Multiple qualified suppliers
• Predictable lot-to-lot performance
• Broad regulatory acceptance
• Low formulation-change risk

Povidone K30 meets those requirements in most markets. Once qualified in a commercial formulation, replacement can require comparative dissolution testing, stability work, supplier qualification, and regulatory documentation.

Oral solid-dose expansion in emerging markets

Demand is strongest in India, China, Southeast Asia, Latin America, and parts of the Middle East, where tablet and capsule production continues to expand. These markets are price-sensitive, but local manufacturers increasingly require pharmaceutical-grade documentation, auditability, and impurity control.

Amorphous solid dispersions

Povidone K30 and related PVP grades can stabilize amorphous drug forms and improve apparent solubility. This application has greater technical value than conventional tablet binding but is not always the preferred polymer. Copovidone, hydroxypropyl cellulose, and specialized graft copolymers may offer better performance for some poorly soluble active ingredients.

The growth opportunity is real but limited by the need to control residual solvent, moisture uptake, polymer-drug compatibility, and physical stability.

Contract manufacturing and formulation outsourcing

Contract development and manufacturing organizations use standard excipients across multiple client programs. A supplier with global documentation, reliable change control, and regional inventory can win business beyond the underlying volume growth of pharmaceutical production.

Who manufactures Povidone K30?

The principal commercial suppliers include BASF, Ashland, and manufacturers based in China and other Asian production centers.

Supplier	Product or portfolio	Market position
BASF	Kollidon povidone grades, including Kollidon 30	Global pharmaceutical excipient supplier with extensive regulatory support
Ashland	Plasdone povidone grades, including K-29/32 and related polymers	Major specialty excipient and formulation-support supplier
Chinese manufacturers	Multiple pharmaceutical-grade PVP K30 products	Competitive pricing and expanding export reach
Regional distributors	Repackaged or locally stocked material	Important for smaller pharmaceutical customers

BASF markets Kollidon 30 as a pharmaceutical povidone used for binding, solubilization, and stabilization. Ashland markets Plasdone polymers for pharmaceutical formulation and oral solid-dose applications (BASF, 2024; Ashland, 2024).

The competitive split is based on more than price. Multinational suppliers compete on technical service, regulatory packages, global supply continuity, and consistency across manufacturing sites. Asian suppliers compete strongly on cost, regional proximity, and flexible order quantities.

How does Povidone K30 pricing work?

Povidone K30 pricing depends on grade, order size, packaging, origin, qualification status, and supply conditions. Pharmaceutical-grade material generally commands a premium over industrial or technical PVP.

Key pricing variables include:

Variable	Effect on price
Pharmaceutical versus industrial grade	Pharmaceutical grade carries a premium
Compendial compliance	USP-NF, Ph. Eur., JP, and other compliance increases qualification value
Residual monomer and peroxide limits	Tighter specifications increase production and testing costs
Order volume	Large annual contracts reduce unit pricing
Packaging	Small drums and specialty packaging increase delivered cost
Freight and regional inventory	Materially affects landed price
Supplier qualification	Approved suppliers have stronger retention and pricing power
N-vinylpyrrolidone input costs	Influences polymer cost base
Energy and labor	Important for polymerization, drying, and packaging

Contract pricing is more common than transparent spot pricing. Pharmaceutical customers often negotiate annual or multi-year supply agreements, with adjustments linked to raw-material, energy, freight, or inflation indices.

Price competition is strongest for unqualified or newly qualified supply. Once a supplier is embedded in a marketed drug product, switching costs reduce price elasticity. A customer can still dual-source, but technical and regulatory work limits rapid substitution.

What is the financial trajectory for Povidone K30 suppliers?

Povidone K30 is financially attractive because it combines recurring demand with relatively low formulation substitution risk. It is not usually a high-growth product by itself. The stronger financial profile comes from portfolio economics, where Povidone K30 supports sales of other excipients, formulation services, and specialty polymers.

Base-case outlook

Period	Expected market behavior
2024-2026	Stable pharmaceutical demand, continued qualification of Asian suppliers, periodic raw-material volatility
2026-2028	Moderate volume growth from generic production and emerging-market expansion
2028 onward	Greater mix shift toward specialty polymers, high-purity grades, and solubility applications

A reasonable base case is low-to-mid single-digit annual volume growth, with revenue growth slightly higher where suppliers raise prices or shift customers toward premium grades. The strongest growth should come from specialty formulation uses rather than traditional wet-granulation binding.

Bull case

The upside scenario includes:

• Faster growth in generic tablet manufacturing
• Increased use in amorphous solid dispersions
• Greater outsourcing to contract manufacturers
• Supply disruptions that support price increases
• Qualification of higher-purity grades in regulated markets
• Stronger pharmaceutical production in India and Southeast Asia

Bear case

The downside scenario includes:

• Excess capacity among Asian manufacturers
• Declining binder use through direct compression
• Substitution by copovidone or cellulose-based excipients
• Raw-material deflation
• Customer pressure to dual-source at lower prices
• Slower oral solid-dose growth in mature markets

How strong is the Povidone K30 supplier landscape?

The patent estate is weak as a barrier to entry because the underlying PVP chemistry and standard pharmaceutical applications are long established. Competitive strength comes from manufacturing execution and regulatory qualification.

Supplier defensibility is highest in four areas:

1. Consistent molecular-weight distribution and viscosity.
2. Low residual N-vinylpyrrolidone and controlled impurity profiles.
3. Validated GMP production and audit history.
4. Global documentation, change control, and supply reliability.

Manufacturing barriers include polymerization know-how, heat and mass-transfer control, drying, milling, packaging, and analytical testing. A new producer can manufacture PVP K30, but obtaining reliable pharmaceutical customers requires a technical dossier, validated processes, stability data, quality agreements, and customer-specific qualification.

What patents protect Povidone K30?

No core composition patent meaningfully protects conventional Povidone K30 as a commodity pharmaceutical excipient. The relevant intellectual-property assets are more likely to involve:

• Manufacturing processes
• Polymerization conditions
• Purification and residual-monomer reduction
• Particle-size engineering
• Co-processed excipient systems
• Drug-polymer formulations
• Amorphous solid dispersions
• Proprietary grades and trademarks

Kollidon and Plasdone are commercial brands rather than patent-based exclusivity positions. The underlying excipient is broadly available from competing manufacturers.

Are there Paragraph IV challenges involving Povidone K30?

Paragraph IV litigation applies to patents listed for approved drug products in the FDA Orange Book. It does not apply to Povidone K30 as a standalone excipient. A generic applicant may use Povidone K30 in a product that faces a Paragraph IV challenge, but the challenge concerns the drug product’s active ingredient, formulation, method of use, or manufacturing patents.

Does Povidone K30 have Orange Book exclusivity?

Povidone K30 has no standalone Orange Book listing or regulatory exclusivity. The FDA Orange Book lists approved drug products and associated patents, not ordinary excipients sold as independent raw materials (U.S. Food and Drug Administration, 2024).

What is the FDA and global regulatory status of Povidone K30?

Povidone is a recognized pharmaceutical excipient with compendial standards and extensive historical use. Regulatory acceptance does not eliminate the need for customer-specific qualification.

Important regulatory considerations include:

• USP-NF monograph compliance
• European Pharmacopoeia compliance
• Japanese Pharmacopoeia compliance where relevant
• Residual N-vinylpyrrolidone
• Peroxide and aldehyde levels
• Microbial quality
• Elemental impurities
• Nitrosamine risk assessment where applicable
• Extractables and leachables for specialized packaging or delivery systems
• Supplier change-control history

FDA’s Inactive Ingredient Database provides a reference point for prior use of excipients in approved drug products, including route, dosage form, and maximum potency information where available (U.S. Food and Drug Administration, 2024).

The regulatory risk is higher in injectables, ophthalmics, inhalation products, and complex delivery systems than in conventional tablets. Povidone K30 is most commercially secure in oral solid-dose formulations.

What manufacturing and supply-chain risks affect Povidone K30?

The principal risks are upstream feedstock exposure, concentration of pharmaceutical-grade capacity, and logistics.

N-vinylpyrrolidone is the key monomer input. Production economics are affected by feedstock pricing, energy costs, plant utilization, and environmental controls. Polymerization and drying consume meaningful energy, making European production more exposed to energy-cost volatility than lower-cost Asian production.

Supply-chain risks include:

• Dependence on a limited number of qualified plants
• Cross-border freight interruptions
• Batch rejection caused by impurity or viscosity deviations
• Regulatory changes affecting residual monomers
• Customer concentration among large generic manufacturers
• Long qualification cycles for replacement suppliers

A dual-source strategy is commercially valuable, but secondary suppliers must match viscosity, molecular-weight distribution, water content, microbial controls, and dissolution performance. A nominally equivalent K30 grade may not behave identically in a specific formulation.

How does Povidone K30 compare with competing binders?

Excipient	Main advantage	Main limitation versus Povidone K30
Copovidone	Strong binding and solubility performance	More specialized and sometimes more expensive
Crospovidone	Excellent disintegration	Not a direct binder substitute in every process
Hypromellose	Film formation and controlled-release utility	Different viscosity and processing behavior
Hydroxypropyl cellulose	Binding and solubility support	Less universal historical adoption
Pregelatinized starch	Low cost and broad availability	Variable functionality and moisture sensitivity
Microcrystalline cellulose	Direct compression and dry binding	Limited solubilization function
Povidone K90	Higher viscosity and stronger polymeric effect	Less suitable where low viscosity is needed

Povidone K30 remains competitive because it performs multiple functions and is familiar to formulation scientists. Its main competitive weakness is that some newer or coprocessed excipients can reduce unit operations or improve direct-compression performance.

What generic launch risks exist for Povidone K30-containing drugs?

Povidone K30 itself rarely creates generic-entry risk. The relevant risks are formulation-specific:

• The excipient may affect dissolution or bioequivalence.
• A change in supplier may require comparative testing.
• Povidone can interact with the active ingredient through hydrogen bonding or peroxide-mediated degradation.
• Moisture uptake can alter stability.
• A drug product may be protected by formulation or manufacturing patents that cover the use of a polymer system.

For standard immediate-release tablets, Povidone K30 usually supports generic development rather than obstructing it. For poorly soluble drugs, long-acting systems, and amorphous dispersions, the polymer can become part of a more valuable formulation patent estate.

What licensing deals and litigation affect Povidone K30?

Commercial licensing is generally more relevant to branded excipient platforms, formulation technologies, and manufacturing processes than to commodity Povidone K30. Supplier relationships are usually governed by distribution agreements, quality agreements, technical-service arrangements, and long-term supply contracts.

There is no evident standalone exclusivity structure comparable to a patented active pharmaceutical ingredient. Litigation risk is more likely to arise from:

• Drug-product formulation patents
• Process patents using PVP or copovidone
• Trade-secret disputes involving polymer production
• Supply and quality claims
• Trademark or product-authenticity disputes

Key Takeaways

• Povidone K30 is a mature, globally used pharmaceutical excipient centered on tablet binding, solubilization, and stabilization.
• Demand is linked to generic medicines, oral solid-dose production, and emerging-market pharmaceutical growth.
• The likely market trajectory is low-to-mid single-digit volume growth, with stronger revenue growth for premium pharmaceutical grades.
• BASF and Ashland are major multinational suppliers; Asian producers are increasing price and supply-chain competition.
• Core patent protection is not a meaningful barrier. Manufacturing quality, impurity control, GMP history, and regulatory documentation are the main competitive defenses.
• Povidone K30 has no standalone Orange Book exclusivity and does not create independent Paragraph IV exposure.
• The strongest growth opportunity is in specialty solubility and amorphous-solid-dispersion applications.
• Financial performance depends more on portfolio mix, raw-material costs, and qualification retention than on Povidone K30 volume alone.

FAQs About Povidone K30 Market and Commercial Outlook

Is Povidone K30 the same as polyvinylpyrrolidone?

Yes. Povidone is the pharmaceutical name for polyvinylpyrrolidone, or PVP. K30 identifies a viscosity and molecular-weight grade.

Which Povidone K30 supplier is strongest for regulated markets?

BASF and Ashland have the strongest multinational regulatory and technical-service positions. Qualified Chinese manufacturers are increasingly competitive on cost and regional supply.

Can Povidone K30 be replaced without regulatory work?

Usually not without qualification. The replacement may require comparative formulation, dissolution, stability, and supplier-validation work, especially for marketed products.

Is Povidone K30 suitable for injectable drugs?

Potentially, but suitability is formulation-specific. Injectable use requires tighter control of impurities, bioburden, endotoxins, particulates, and sterilization compatibility than ordinary tablet applications.

What is the difference between Povidone K30 and Povidone K90?

Povidone K90 has higher viscosity and generally higher molecular weight. Povidone K30 is more commonly selected for tablet binding and solubilization where lower solution viscosity improves processing.

References

Ashland. (2024). Plasdone povidone and copovidone polymers for pharmaceutical applications. https://www.ashland.com

BASF. (2024). Kollidon pharmaceutical excipients. https://pharma.basf.com

European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. Council of Europe. https://www.edqm.eu

United States Pharmacopeia. (2024). Povidone monograph. In USP-NF. United States Pharmacopeial Convention. https://www.uspnf.com

U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/、】【